A man living with bile duct cancer is urgently calling on the National Health Service (NHS) to approve a potentially life-extending drug, zanidatamab, for wider use. His plea comes as the National Institute for Health and Care Excellence (NICE) considers whether to recommend the treatment, sparking a debate about access to innovative cancer therapies within the UK’s healthcare system.
The case highlights the challenges faced by patients with cholangiocarcinoma, a relatively rare and aggressive cancer of the bile ducts. Currently, treatment options are limited, and the prognosis can be poor. Zanidatamab, a HER2-targeted antibody, offers a new hope for some patients, but its availability remains restricted.
The patient, identified as Honeybone, experienced a remarkable response to zanidatamab after initial treatments proved insufficient. Following surgery and chemotherapy for a first tumor, a subsequent tumor was detected. After receiving zanidatamab in combination with standard treatments, scans revealed no evidence of remaining cancer. “I’m one of the lucky ones, living a normal life again, thanks to zanidatamab,” he stated. “I’m back at work full-time – unlike when I was having chemo and immunotherapy, when I couldn’t work – and I was able to visit my brother in Australia over Christmas.”
Yet, NICE has not yet recommended zanidatamab for routine use on the NHS. A spokesperson for NICE explained that while the evidence suggests the drug “is likely to help people live longer and delay their cancer getting worse,” “significant questions that still require answering” remain regarding the extent of its benefit and how it compares to other available treatments. The committee was unable to make a positive recommendation based on the evidence submitted by the pharmaceutical company at the initial meeting.
Zanidatamab Shows Promise in HER2-Positive Bile Duct Cancer
Zanidatamab is designed to target HER2, a protein that can be overexpressed in some cancers, including a subset of bile duct cancers. Recent research has demonstrated its potential to significantly improve outcomes for patients with HER2-positive cholangiocarcinoma. A study published by CancerNetwork showed a “meaningful benefit” for patients with this specific type of cancer. Another report from OncLive suggested the drug, when used in combination with other therapies, may be a “game changer” for frontline management of HER2+ GEA (gastroesophageal adenocarcinoma).
Despite these promising findings, NICE’s initial assessment raised concerns about the cost-effectiveness of zanidatamab and the need for further data. The organization’s independent committee carefully reviewed the available evidence, seeking clarity on the drug’s overall benefit and its position relative to existing treatment options.
Concerns Over Inequality of Access
Honeybone expressed concern that limiting access to zanidatamab through the NHS could exacerbate existing inequalities in cholangiocarcinoma care. He fears that patients who cannot access clinical trials or afford private healthcare may be denied potentially life-saving treatment. “I’m concerned that not approving this treatment for NHS patients will add to the inequalities in cholangiocarcinoma care we are already seeing – with people who are able to access clinical trials or have private healthcare benefiting from new life-extending treatments, and those that can’t go on a trial or afford to pay for insurance, not surviving,” he said.
The situation underscores a broader debate about the balance between innovation, cost, and equitable access to healthcare. Recent reports highlight similar challenges with other new cancer drugs, as health systems grapple with how to fund and deliver cutting-edge therapies to those who need them.
NICE is expected to revisit its assessment of zanidatamab as additional data becomes available. The outcome of this review will have significant implications for patients with HER2-positive bile duct cancer in England, Wales, and Northern Ireland, where NICE guidance is typically followed.
The ongoing evaluation of zanidatamab serves as a critical reminder of the need for continued research, transparent decision-making, and a commitment to ensuring that all patients have access to the best possible care.
Disclaimer: This article provides informational content only and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
What are your thoughts on the challenges of accessing innovative cancer treatments? Share your perspective in the comments below.
